TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT04965675: A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

Sponsor: H. Lundbeck A/S · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 285 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$4,242,392

Rescue Site Savings

+$2,809,896

Unlock Full NCT04965675 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04965675 Rescue Dossier →